Cardiac Monitoring And Cardiac Rhythm Management Devices Market (2025 - 2033)

Cardiac Monitoring And Cardiac Rhythm Management Devices Market Summary

The global cardiac monitoring and cardiac rhythm management devices market size was estimated at USD 21.84 billion in 2024 and is projected to reach USD 32.34 billion by 2033, growing at a CAGR of 4.45% from 2025 to 2033. Increasing cardiovascular incidence is one of the key factors driving the market's growth.

According to an Oxford Academic article published in January 2025, the global age-standardized prevalence of cardiovascular disease reaches about 7,179 cases per 100,000 people, emphasize the significant and ongoing impact of heart conditions globally. Such widespread prevalence means that millions are living with diseases that require careful monitoring and timely intervention to prevent complications. This fuels demand for cardiac monitoring and cardiac rhythm management devices, which are critical for identifying abnormal heart rhythms, managing chronic heart conditions, and reducing the risk of serious cardiac events.

Increasing awareness campaigns and government-initiated screening programs for early detection of CVDs contribute to market expansion by ensuring more patients receive timely diagnosis and treatment. According to an article published by Hearst Newspapers II, LLC in June 2025, Midland Memorial Hospital, working alongside the Championship Hearts Foundation, conducts free ECG and limited echocardiogram screenings for teenagers between 14 and 18 years old. In previous events, these screenings identified severe, potentially life-threatening heart conditions, such as hypertrophic cardiomyopathy, in approximately 1 out of every 250 participants. Initiatives like this highlight the critical role of early detection in preventing sudden cardiac events among young people. They also emphasize the growing need for portable ECG devices and advanced rhythm-monitoring technologies tailored for pediatric and adolescent populations, contributing to expanding the cardiac monitoring and cardiac rhythm management devices market.

Furthermore, according to the American Heart Association, Inc. article published in November 2023, the 2023 guidelines issued by the American Heart Association (AHA), American College of Cardiology (ACC), American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS) emphasize the importance of increasing awareness and incorporating routine screening for atrial fibrillation (AFib), especially among high-risk groups like older adults. These recommendations advocate for regular pulse and ECG screenings to facilitate early diagnosis and effective treatment. Detecting and managing AFib promptly is vital because it can substantially reduce the risk of stroke and other serious health problems. This focus on proactive screening and education drives up demand for cardiac monitoring and rhythm management devices, which are essential for identifying heart rhythm disorders and guiding proper medical care, thereby boosting market growth.

The efficiency of targeted screening programs for CVDs fuels market growth. According to Springer Nature, in June 2024,a review of cardiology reports examines the impact of screening programs. It highlights findings from multicenter studies, such as AF-SCREEN and STROKESTOP, which show that targeted screening greatly enhances the detection of CVDs, especially among older adults. The review strongly supports establishing national screening initiatives to address the growing burden of AFib-related complications, highlighting the critical role of early detection and intervention.

The technologically advanced products offered by the key players drive the market's growth. For instance, in April 2025, LifeSignals, Inc. introduced the UbiqVue 2AYe Holter System at Heart Rhythm 2025. This new Holter monitoring solution, distributed in collaboration with UltraLinQ Healthcare Solutions, is designed to streamline cardiac monitoring workflows by producing diagnostic reports far faster than traditional methods and eliminating the need to mail or physically retrieve the biosensor device.

At the heart of the UbiqVue system is the 2AYe Biosensora, a disposable, chest-worn device capable of continuously recording two-channel ECG and event data for up to five days. Data collected by the biosensor is securely encrypted and sent via a patient-facing mobile app to a cloud-based platform during the monitoring period. Once the Holter test concludes, the patient’s data is quickly analyzed through cloud-based ECG analytics, substantially reducing the review time required by certified cardiac technicians and enabling physicians to access finalized reports within hours.

Market Concentration & Characteristics

The global cardiac monitoring and cardiac rhythm management devices market is characterized by a high degree of innovation, driven by the development of technologically advanced solutions and continuous advancements in pacemaker technology. For instance, in March 2025, MicroPort Scientific Corporation launched the localized TEN pacemaker family in China through its affiliate MicroPort CRM Shanghai. The TEN series includes six compact, long-life models across T, E, and N categories, offering AutoMRI compatibility and the SAM function for continuous sleep and arrhythmia monitoring.

Several market players, such as Stryker, Abbott, Boston Scientific Corporation, and Medtronic, actively engage in mergers and acquisitions within the cardiac monitoring and cardiac rhythm management market. Through these activities, companies pursue key strategies including developing innovative products, forming strategic partnerships, and expanding into new geographic regions. For example, in December 2025, Teleflex Incorporated revealed that it has entered into a definitive agreement to acquire substantially all of BIOTRONIK SE & Co. KG's Vascular Intervention business for an estimated cash payment of approximately €760 million ( USD 839.04 million).

Regulatory oversight significantly aligns the cardiac monitoring and cardiac rhythm management industry. Strict evaluation criteria from agencies such as the FDA and EMA ensure devices meet high patient safety and therapeutic effectiveness standards, often extending development timelines and approval costs. Nevertheless, evolving regulatory pathways, including expedited review programs and digital health frameworks, enable faster clearance of innovative technologies like wearable monitors, implantable loop recorders, and next-generation cardiac rhythm devices. These regulatory shifts support manufacturers in delivering advanced, patient-centric solutions while maintaining rigorous safety and performance standards.

There are currently no direct substitutes. These systems play a vital role in continuous heart rhythm assessment, early detection of abnormalities, and timely therapeutic intervention. Tools such as standard ECGs or periodic check-ups helps identify cardiac issues, however lacks the continuous, high-fidelity monitoring and therapeutic capabilities offered by implantable devices, wearable sensors, and advanced rhythm management solutions. As such, their unique ability to combine diagnostic precision with real-time management remains essential in modern cardiac care.

Key manufacturers operating in the cardiac monitoring and cardiac rhythm management are actively broadening their reach by exploring untapped regional markets, collaborating with local distribution partners, and customizing their product portfolios to meet distinct healthcare needs across various geographies.

Product Insights

By product, the cardiac rhythm management devices segment dominated the market with the largest revenue share of 66.96% in 2024. Cardiac rhythm management (CRM) devices are designed to regulate heart rhythm in patients with arrhythmias, bradycardia, or heart failure. This segment includes implantable devices such as pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems. These devices restore usual cardiac pacing, prevent sudden cardiac death, and improve ventricular synchrony in patients with reduced ejection fraction or conduction delays. Technological advancement drives the growth of the market. In March 2025, MicroPort Scientific Corporation gained CE Mark approval for its SmartView Connect App Mobile, allowing Android-based remote monitoring of Bluetooth-enabled pacemakers, ICDs, and CRT-Ds. The app securely transmits encrypted data to the SmartView network, replacing bedside monitors and supporting real-time, clinic-connected cardiac care across Europe.

The cardiac monitoring devices segment is anticipated to grow at the fastest CAGR over the forecast period. Cardiac monitoring devices are designed to continuously or intermittently assess electrical and hemodynamic cardiac parameters, enabling early detection of arrhythmias, ischemia, and other cardiac events. These systems are essential in acute and ambulatory care, supporting diagnosis, treatment planning, and long-term disease management. Key products in this category include Holter monitors, event recorders, mobile cardiac telemetry systems, and ECG machines used in hospitals and outpatient settings. Technological advancement drives the growth of the market. In February 2025, CB Scientific launched its next-generation MyCardia AT cardiac event monitor across Southeast Asia, Hong Kong, and Macau. The FDA-cleared device offers a lightweight, user-friendly design with smartphone compatibility for up to 30 days of remote ECG monitoring. As local distributors begin regulatory approvals, the company aims to scale its connected cardiac monitoring ecosystem and expand its presence in key global markets.

End Use Insights

By end use, the hospital segment dominated the market by end use, with a revenue share of 55.16% in 2024. Hospitals remain the primary setting for using and adopting cardiac monitoring and cardiac rhythm management (CRM) devices, driven by their capacity to handle high-acuity patients and deliver device-based interventions. Key devices include Holter monitors, telemetry systems, event monitors, ECG machines, pacemakers, ICDs, and CRT devices. Hospitals rely on continuous cardiac monitoring for patients in emergency, intensive care, and perioperative settings to detect arrhythmias, ischemic events, or heart failure decompensation early and intervene accordingly. In November 2024, BioIntelliSense reported results from a 15-month study showing that its chest-worn BioButton device reduced hospital stays for cardiac patients from 3.07 to 2.75 days. The wearable provided early warnings of deterioration 14.8 hours in advance, improving clinical response times. The device continuously tracked heart rate, respiration, and other vitals in over 12,000 patients, enabling 114 new or modified physician orders during monitoring.

The ambulatory surgery centers segment is expected to grow significantly over the forecast period. Ambulatory surgery centers (ASCs) are increasingly involved in the procedural side of cardiac rhythm management, particularly for patients requiring low-risk pacemaker or loop recorder implantation. The shift toward ASCs reflects broader efforts to reduce inpatient burden and procedural costs while maintaining clinical outcomes. These centers typically cater to stable patients and use minimally invasive techniques, supported by portable ECG and device programming tools, to perform device implants and diagnostics with quick turnaround. In February 2024, the American College of Cardiology launched its CV ASC Registry Suite to monitor the rising number of cardiac procedures in ambulatory surgical centers. The registry tracks interventions such as diagnostic catheterization, pacemaker, and defibrillator implantations, key product types in the cardiac rhythm management and monitoring devices market. It provides benchmarking data that may influence product adoption trends in outpatient cardiac care.

Regional Insights

North America dominated the cardiac monitoring and cardiac rhythm management devices market with a revenue share of 48.80% in 2024. Increased prevalence of atrial fibrillation (AFib) drives the growth of the U.S. cardiac monitoring and cardiac rhythm management devices market. According to the American Heart Association article published in March 2025, Atrial fibrillation (AFib), the most prevalent form of irregular heart rhythm, affected about five million individuals across the U.S. in 2024. Projections indicate this number could surpass 12+ million by 2030, reflecting a significant rise in the burden of arrhythmias nationwide. This growing prevalence is a key factor fueling demand for advanced cardiac monitoring tools and cardiac rhythm management devices in North America.

U.S. Cardiac Monitoring And Cardiac Rhythm Management Devices Market Trends

The U.S. dominated the cardiac monitoring and cardiac rhythm management devices market in North America region in 2024. Technologically advanced products launched by key manufacturers drive the market's growth. For instance, in December 2024, HeartBeam, Inc., a medical technology firm dedicated to advancing cardiac care through innovative diagnostic tools, recently announced that it has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HeartBeam system, designed for comprehensive arrhythmia detection. This marks the first FDA clearance for a device of its kind, featuring a unique, patented approach. The HeartBeam system offers a high-fidelity electrocardiogram (ECG) capability within a compact, credit card-sized, wireless design, enabling the capture of heart activity from three different angles to deliver critical insights into cardiac health.

Europe Cardiac Monitoring And Cardiac Rhythm Management Devices Market Trends

The cardiac monitoring and cardiac rhythm management devices market in Europe is expected to grow significantly over the forecast period. The high mortality rate from cardiovascular diseases boosts demand for cardiac monitoring and cardiac rhythm management devices in Europe. According to the WHO article published in May 2024, cardiovascular diseases (CVDs) are the leading cause of disability and premature death in the European Region, responsible for over 42.5% of all deaths annually. This staggering statistic translates to approximately 10,000 deaths every day. The significant impact of CVD emphasizes the urgent need for advanced cardiac monitoring and cardiac rhythm management solutions.

The cardiac monitoring and cardiac rhythm management devices industry in the UK is expected to grow significantly during the forecast period. Growing AFib incidence in the UK drives the growth of the market. According to the British Heart Foundation article published in January 2025, in the UK, over 1.6 million people have been diagnosed with atrial fibrillation (AFib). This communal heart rhythm disorder increases the risk of stroke and other serious complications. Despite many diagnoses, many patients still do not receive optimal treatment or consistent monitoring. This gap in care highlights the urgent need for more advanced solutions to detect, track, and manage AF effectively.

Asia Pacific Cardiac Monitoring And Cardiac Rhythm Management Devices Market Trends

The Asia Pacific cardiac monitoring and cardiac rhythm management devices industry is expected to register the fastest growth rate over the forecast period. Rising elderly population in the Asia Pacific region. According to the United Nations Economic and Social Commission for Asia and the Pacific, in 2023, approximately 697 million individuals aged 60 years or older lived in Asia and the Pacific region, constituting approximately 60% of the global older population. The elderly population is more susceptible to cardiovascular diseases, and the increase in the population is leading to a higher demand for cardiac monitoring and cardiac rhythm management devices.

China's cardiac monitoring and rhythm management devices market is anticipated to grow considerably during the forecast period. Increasing CVD cases drive the growth of the market. According to an NCBI article published in November 2023, China faces a massive health challenge, with an estimated 330 million people affected by cardiovascular diseases, underscoring the country’s growing burden of heart-related conditions. This immense patient pool is fueling demand for advanced cardiac monitoring and rhythm management devices, as healthcare providers strive to improve early detection, precise diagnosis, and effective treatment of conditions such as arrhythmias, heart failure, and coronary artery disease.

Latin America Cardiac Monitoring And Cardiac Rhythm Management Devices Market Trends

The Latin America cardiac monitoring and cardiac rhythm management devices industry is anticipated to witness considerable growth over the forecast period fueled by rising cardiovascular disease incidence, aging populations, and awareness of early diagnosis and preventive care. Countries across the region are increasingly adopting advanced technologies such as implantable monitors, wearable ECG devices, and modern defibrillators to improve patient outcomes. While economic disparities and healthcare infrastructure challenges persist, local and global manufacturers see strong opportunities to drive innovation and market growth in this evolving healthcare landscape.

Argentina's cardiac monitoring and cardiac rhythm management devices industry is anticipated to register considerable growth during the forecast period. Rising adoption of cardiac rhythm devices drives the development of the market. According to an NCBI article published in December 2024, over 22,000 cardiac rhythm management devices were implanted nationwide in 2022, highlighting the growing reliance on advanced cardiac technologies. Moreover, pacemakers accounted for most of these procedures, with approximately 18,699 units implanted, representing 84.1%. This surge in device utilization reflects the increasing burden of arrhythmias and other heart rhythm disorders, as well as the expanding capacity of Argentina’s healthcare system to adopt life-saving rhythm management solutions.

Middle East & Africa Cardiac Monitoring And Cardiac Rhythm Management Devices Market Trends

The Middle East and Africa cardiac monitoring and cardiac rhythm management devices market is anticipated to witness considerable growth over the forecast period, fueled by rising cases of cardiovascular diseases and arrhythmias, and increasing awareness about the benefits of early detection and modern treatments. Countries in the region report higher arrhythmias, heart failure, and other cardiac conditions, prompting greater demand for technologies that help monitor and regulate heart rhythms. Improvements in healthcare infrastructure and efforts to enhance access to medical technologies are boosting market growth.

The UAE cardiac monitoring and cardiac rhythm management devices industry is anticipated to grow considerably during the forecast period. Increasing CVD mortality drives the growth of the market. According to the American Heart Association, Inc., an article published in November 2024, in the United Arab Emirates, cardiovascular diseases remain the foremost health challenge, responsible for 36.7% of all deaths, emphasizing the significant impact of heart-related conditions on public health. This high burden of disease highlights the urgent need for advanced diagnostic and therapeutic solutions to detect and manage heart rhythm disorders effectively.

Key Cardiac Monitoring And Cardiac Rhythm Management Devices Company Insights:

Key participants in the cardiac monitoring and cardiac rhythm management devices industry focus on devising innovative business growth strategies, such as expanding their product portfolios, partnerships and collaborations, mergers and acquisitions, and business footprints.

Recent Developments

• In June 2024, Stryker launched the LIFEPAK 35 monitor/defibrillator to support advanced life support in both EMS and hospital settings. The device features an intuitive touchscreen, real-time data connectivity, and ergonomic design. It aims to reduce cognitive burden and improve response efficiency for frontline providers.

• In May 2024, Koninklijke Philips N.V. rolled out its wearable ePatch and AI-powered Cardiologs analytics platform to 14 hospitals across Spain. The solution supports long-term ambulatory cardiac monitoring, enabling early detection of atrial fibrillation and reducing emergency room burden. Clinical use at Vall d’Hebron Hospital led to shorter stays and cost savings.

• In April 2024, MicroPort Scientific Corporation launched TALENTIA and ENERGYA, its new Bluetooth-enabled ICD and CRT-D ranges in Europe. These devices offer advanced remote monitoring, MRI compatibility, and the exclusive SonR hemodynamic optimization sensor. A modern tablet programmer interface was also introduced to streamline patient management and follow-up.

Cardiac Monitoring And Cardiac Rhythm Management Devices Market